Sartorius Stedim Biotech S.A.
SDMHFOTCHealthcare● Active
$206.01
$-4.99(-2.36%)
Market Cap$20.0B
P/E Ratio—
52W High$264.3
52W Low$178.3
Sartorius Stedim Biotech S.A. (SDMHF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · SDMHF · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.97B | $2.78B | $2.78B | $3.49B | $2.89B |
| Cost of Revenue | $1.62B | $1.57B | $1.54B | $1.66B | $1.33B |
| Gross Profit | $1.34B | $1.21B | $1.23B | $1.82B | $1.55B |
| Gross Margin %(computed) | 45.33% | 43.41% | 44.44% | 52.03% | 53.79% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.14B | $0.15B | $0.15B | $0.11B |
| G&A Expenses | $0.00B | $0.17B | $0.17B | $0.15B | $0.13B |
| Total Operating Expenses | $0.80B | $0.84B | $0.77B | $0.76B | $0.67B |
| Operating Income | $0.55B | $0.37B | $0.45B | $1.05B | $0.90B |
| Operating Margin %(computed) | 18.50% | 13.33% | 16.20% | 30.15% | 31.02% |
| Interest Income | $0.01B | $0.02B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.15B | $0.16B | $0.12B | $0.02B | $0.01B |
| Income Before Tax | $0.37B | $0.22B | $0.40B | $1.13B | $0.65B |
| Income Tax Expense | $0.11B | $0.04B | $0.09B | $0.25B | $0.23B |
| Net Income | $0.27B | $0.18B | $0.31B | $0.88B | $0.41B |
| Net Margin %(computed) | 8.95% | 6.30% | 11.16% | 25.08% | 14.35% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $2.73 | $1.81 | $3.36 | $9.51 | $4.50 |
| Wtd Avg Shares | 0.10B | 0.10B | 0.09B | 0.09B | 0.09B |
| EBITDA | $0.84B | $0.67B | $0.76B | $1.33B | $0.80B |
| EBITDA Margin %(computed) | 28.43% | 24.12% | 27.23% | 38.10% | 27.67% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · EUR · B
Explore more Sartorius Stedim Biotech S.A. data
About Sartorius Stedim Biotech S.A. (SDMHF) Income Statement
Sartorius Stedim Biotech S.A. (SDMHF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, SDMHF reported revenue of $2.97B, gross profit of $1.34B (gross margin 45.33%), and net income of $0.27B — a net profit margin of 8.95%.
Frequently asked questions
SDMHF · 4 questionsSartorius Stedim Biotech S.A. (SDMHF) reported revenue of $2.97B for 2025, up 6.7% year-over-year.
SDMHF revenueSDMHF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08